The evolution of direct transcranial photobiomodulation: a history of dose, depth, and delivery
- 1NeuroThera , , ,
- 2UF Innovate | Ventures, University of Florida , , ,
Abstract
Direct transcranial photobiomodulation (dtPBM) delivers red or near-infrared light through the scalp and skull with the aim of affecting brain tissue. The field has produced encouraging findings but inconsistent clinical results. We reconstruct its development as a history of scientific and engineering decisions in which optical access, target depth, and dose repeatedly shaped what could be tested. The clinical lineage began with light therapy for ischemic myocardium and moved to stroke, where cadaver measurements established that near-infrared light could traverse the human scalp and skull and defined a historical design target of approximately 7.5 mW/cm ² at the dura. The NEST clinical program then carried a fixed 808-nm regimen into three stroke trials: NEST-1 met its primary endpoint, NEST-2 showed a nonsignificant overall trend (p = 0.094) with a published post hoc signal in moderate stroke (p = 0.044), and NEST-3 stopped for futility. An unpublished, exploratory NEST-2 reanalysis described larger treatment differences for superficial lesions; this observation motivates prospective testing but does not establish depth-dependent efficacy. After NEST, treatment moved to the forehead, where target geometry was more reproducible. The ELATED trials adopted a more practical LED platform at substantially lower irradiance while preserving broadly similar treatment-site radiant exposure, whereas the TRIADE R61 trial deliberately varied optical parameters and found optical-parameter-dependent, bidirectional BOLD power responses. The historical record also leaves biological mechanism unresolved: mitochondrial/redox, neurovascular, glial-inflammatory, network-mediated, and diffuse or systemic pathways remain plausible at different levels of evidence, and a distributed physiological response does not by itself identify where the effect begins. These observations support a constrained historical inference: dose, depth, and delivery site are biological variables, not merely device specifications. We distinguish focal-local, diffuse/systemic, and local-stimulation/network-mediated accounts of action and identify prospective tests that can discriminate among them. The next phase of dtPBM development should prioritize indications in which optical access, target engagement, and a disease-relevant network or biomarker can be specified prospectively rather than inferred after a clinical outcome.
Related
- Transcranial photobiomodulation rebalances cortical excitation/inhibition in young adults with attention deficit/hyperactivity disorder
- Micro-CT-informed Monte Carlo and experimental dosimetry of transcranial photobiomodulation devices
- Trajectories of cardiopulmonary adaptation and executive function in elite endurance athletes receiving transcranial direct current stimulation with interval training
- Fronto-temporal transcranial direct current stimulation reduces symptoms in treatment-resistant schizophrenia: a randomized sham-controlled trial
- Effects of transcranial direct current stimulation on gait and balance under dual-task conditions in older adults: a systematic review and meta-analysis
BibTeX
@article{taboada2026evolution,
title = {{The evolution of direct transcranial photobiomodulation: a history of dose, depth, and delivery}},
author = {Luis De Taboada and Jackson Streeter},
journal = {Frontiers in psychiatry},
year = {2026},
month = oct,
doi = {10.3389/fpsyt.2026.1970464},
url = {https://europepmc.org/article/PMC/PMC13690807},
note = {CC BY},
}
RIS
TY - JOUR
TI - The evolution of direct transcranial photobiomodulation: a history of dose, depth, and delivery
AU - Luis De Taboada
AU - Jackson Streeter
PY - 2026
DA - 2026/10/09
JO - Frontiers in psychiatry
DO - 10.3389/fpsyt.2026.1970464
UR - https://europepmc.org/article/PMC/PMC13690807
AB - Direct transcranial photobiomodulation (dtPBM) delivers red or near-infrared light through the scalp and skull with the aim of affecting brain tissue. The field has produced encouraging findings but inconsistent clinical results. We reconstruct its development as a history of scientific and engineering decisions in which optical access, target depth, and dose repeatedly shaped what could be tested. The clinical lineage began with light therapy for ischemic myocardium and moved to stroke, where cadaver measurements established that near-infrared light could traverse the human scalp and skull and defined a historical design target of approximately 7.5 mW/cm ² at the dura. The NEST clinical program then carried a fixed 808-nm regimen into three stroke trials: NEST-1 met its primary endpoint, NEST-2 showed a nonsignificant overall trend (p = 0.094) with a published post hoc signal in moderate stroke (p = 0.044), and NEST-3 stopped for futility. An unpublished, exploratory NEST-2 reanalysis described larger treatment differences for superficial lesions; this observation motivates prospective testing but does not establish depth-dependent efficacy. After NEST, treatment moved to the forehead, where target geometry was more reproducible. The ELATED trials adopted a more practical LED platform at substantially lower irradiance while preserving broadly similar treatment-site radiant exposure, whereas the TRIADE R61 trial deliberately varied optical parameters and found optical-parameter-dependent, bidirectional BOLD power responses. The historical record also leaves biological mechanism unresolved: mitochondrial/redox, neurovascular, glial-inflammatory, network-mediated, and diffuse or systemic pathways remain plausible at different levels of evidence, and a distributed physiological response does not by itself identify where the effect begins. These observations support a constrained historical inference: dose, depth, and delivery site are biological variables, not merely device specifications. We distinguish focal-local, diffuse/systemic, and local-stimulation/network-mediated accounts of action and identify prospective tests that can discriminate among them. The next phase of dtPBM development should prioritize indications in which optical access, target engagement, and a disease-relevant network or biomarker can be specified prospectively rather than inferred after a clinical outcome.
SN - 1664-0640
ER -